- Home
- PLRX vs MLYS Comparison
PLRX vs MLYS Comparison
Compare PLRX & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- MLYS
- Stock Information
- Founded
- PLRX 2015
- MLYS 2019
- Country
- PLRX United States
- MLYS United States
- Employees
- PLRX N/A
- MLYS N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- PLRX Health Care
- MLYS Health Care
- Exchange
- PLRX Nasdaq
- MLYS Nasdaq
- Market Cap
- PLRX 77.3M
- MLYS 1.0B
- IPO Year
- PLRX 2020
- MLYS 2023
- Fundamental
- Price
- PLRX $1.39
- MLYS $14.63
- Analyst Decision
- PLRX Hold
- MLYS Strong Buy
- Analyst Count
- PLRX 10
- MLYS 4
- Target Price
- PLRX $9.79
- MLYS $27.00
- AVG Volume (30 Days)
- PLRX 1.7M
- MLYS 885.1K
- Earning Date
- PLRX 08-06-2025
- MLYS 08-12-2025
- Dividend Yield
- PLRX N/A
- MLYS N/A
- EPS Growth
- PLRX N/A
- MLYS N/A
- EPS
- PLRX N/A
- MLYS N/A
- Revenue
- PLRX N/A
- MLYS N/A
- Revenue This Year
- PLRX N/A
- MLYS N/A
- Revenue Next Year
- PLRX N/A
- MLYS N/A
- P/E Ratio
- PLRX N/A
- MLYS N/A
- Revenue Growth
- PLRX N/A
- MLYS N/A
- 52 Week Low
- PLRX $1.10
- MLYS $8.24
- 52 Week High
- PLRX $16.10
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- PLRX 53.02
- MLYS 54.08
- Support Level
- PLRX $1.13
- MLYS $14.07
- Resistance Level
- PLRX $1.50
- MLYS $14.70
- Average True Range (ATR)
- PLRX 0.11
- MLYS 0.69
- MACD
- PLRX 0.03
- MLYS 0.15
- Stochastic Oscillator
- PLRX 71.23
- MLYS 80.69
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.